WASHINGTON, D.C. — In a sweeping move aimed at reshaping prescription drug access and affordability, President Donald Trump on Tuesday announced the launch of TrumpRx, a new government-backed website allowing Americans to purchase medications directly—bypassing insurance companies and pharmacy middlemen.
Standing on the South Lawn of the White House, Trump, 79, described the initiative as “one of the biggest things we’ll do,” predicting it will save Americans “hundreds of millions of dollars a year.” As part of the announcement, pharmaceutical giant Pfizer has agreed to slash prices on a wide range of medications, with discounts reaching up to 85%.
“In some cases, we’ll be reducing drug prices by 100%, 300% or more,” Trump said, emphasizing the initiative’s impact on reducing costs for Medicaid recipients in particular.
Most Favored Nation Pricing & Direct Access
The president explained that Pfizer will offer all its prescription drugs to Medicaid at “most favored nation” (MFN) pricing—a strategy that benchmarks U.S. prices against the lowest rates paid in other wealthy countries.
New medications introduced by Pfizer will also be subject to MFN pricing for American consumers. The TrumpRx platform will offer direct-to-consumer sales at these lower rates.
Key examples of drug price cuts include:
- Xeljanz (Rheumatoid Arthritis): 40% discount
- Zavzpret (Migraines): 50% discount
- Eucrisa (Dermatitis): 80% discount
- Duavee (Osteoporosis): 85% discount
Pfizer to Invest $70 Billion in U.S. Manufacturing
In addition to the pricing overhaul, Pfizer has committed to investing $70 billion in bringing pharmaceutical manufacturing and research back to the U.S.
“It’s a historic day. We are turning the tide and reversing an unfair situation,” said Pfizer CEO Albert Bourla alongside Trump in the Oval Office.
Medicare Director Chris Klomp highlighted that the TrumpRx site will offer pricing transparency, stating, “This is bypassing middlemen. In many instances, prices are 80% lower than they are today.”
Push for Domestic Manufacturing and Upcoming Tariffs
The announcement comes just one day before a new Trump administration policy deadline requiring pharmaceutical companies to begin manufacturing in the U.S.—or face steep penalties.
“Starting October 1st, 2025, we will be imposing a 100% tariff on any branded or patented pharmaceutical product, unless a company is building their manufacturing plant in America,” Trump wrote on Truth Social last week.
Companies already investing in domestic facilities will be exempt from the tariffs.
Political Impact and Pushback
Health and Human Services Secretary Robert F. Kennedy Jr. credited Trump’s hands-on approach for pushing the deal across the finish line.
“He harangued and harassed us to get this done,” Kennedy said. “At one point, [CMS Administrator] Dr. [Mehmet] Oz told me, ‘I can’t take the president’s calls anymore.’”
White House spokesperson Kush Desai contrasted the administration’s move with Democratic priorities, stating:
“While Democrats threaten to shut down the government to subsidize healthcare for illegal immigrants, President Trump is leveraging federal power to drastically cut drug prices for everyday Americans.”
